Monopar Therapeutics: A Healthy Dose Of Skepticism Warranted [Seeking Alpha]
Monopar Therapeutics Inc. (MNPR)
Company Research
Source: Seeking Alpha
ALXN-1840, acquired from AstraZeneca, targets Wilson disease with an NDA filing anticipated in early 2026, but approval remains uncertain. MNPR's radiopharmaceutical pipeline is in early stages, with limited data and no clear timeline for further results. An analysis around this remarkable biotech comeback story follows in the paragraphs below. Looking for a helping hand in the market? Members of The Busted IPO Forum get exclusive ideas and guidance to navigate any climate. Learn More » MadamLead/iStock via Getty Images Shares of biopharmaceutical concern Monopar Therapeutics Inc. ( NASDAQ: MNPR ) have had an absolutely massive surge in the past year after being left for dead with cash of $7.1 million and a market cap under $9 million. Its acquisition of Wilson disease candidate ALXN-1840 More on my IG service Author's note: I present and update my best small-cap Busted IPO stock ideas only to subscribers of my exclusive marketplace, The Busted IPO Forum . Try a free 2-
Show less
Read more
Impact Snapshot
Event Time:
MNPR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MNPR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MNPR alerts
High impacting Monopar Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
MNPR
News
- Is Monopar Therapeutics Inc. (NASDAQ:MNPR) Trading At A 46% Discount? [Yahoo! Finance]Yahoo! Finance
- Monopar Therapeutics (NASDAQ:MNPR) was downgraded by analysts at Raymond James Financial, Inc. from a "strong-buy" rating to an "outperform" rating.MarketBeat
- Monopar Therapeutics GAAP EPS of -$0.48 misses by $0.05 [Seeking Alpha]Seeking Alpha
- Monopar Therapeutics Reports Third Quarter 2025 Financial Results and Recent Developments [Yahoo! Finance]Yahoo! Finance
- Monopar Therapeutics Reports Third Quarter 2025 Financial Results and Recent DevelopmentsGlobeNewswire
MNPR
Earnings
- 11/13/25 - Miss
MNPR
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- 11/13/25 - Form 8-K
- MNPR's page on the SEC website